Novo Nordisk Makes Additional Equity Investment in Aspect Biosystems and Expands Multi-Billion Dollar Partnership

Novo Nordisk and Vancouver-based Aspect Biosystems announce a new phase of their partnership

On January 20, 2026 Novo Nordisk (“Novo”) and Vancouver-based Aspect Biosystems (“Aspect”), announced a new phase of their partnership focused on developing curative cell therapies for type 1 diabetes (T1D). Since 2023, Aspect and Novo have worked together on technologies aimed at producing insulin-secreting islet cells from stem cells. Under the revised partnership, Aspect has acquired Novo’s stem cell–derived islet and hypoimmune cell engineer…

Novo Nordisk Makes Additional Equity Investment in Aspect Biosystems and Expands Multi-Billion Dollar Partnership

Aspect Biosystems and big pharma giant from Novo Nordisk announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes. Since 2023, Aspect and Novo Nordisk have collaborated to develop cellular medicines designated to replace, repair, or supplement biological functions to deliver truly disease-modifying therapies. This new phase of the partnership builds on the momentum achieved in the existing …